AliceScottMimsMDMSCR

PubMed

• Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (m) acute myeloid leukemia (AML).
  Brian A Jonas, Andrew H Wei, Pau Montesinos, P Brent Ferrell, Karen Wl Yee, Pierre Fenaux, Anthony Schwarer, Jorge Cortes, Gary Schiller, Alice Mims, Gail J Roboz, Jus...> ;Leukemia & Lymphoma. 2024 Mar 27
• The multi-CDK inhibitor dinaciclib reverses bromo- and extra-terminal domain (BET) inhibitor resistance in acute myeloid leukemia via inhibition of Wnt/β-catenin signa...
  Alexander R Marr, Madeline Halpin, Dominique L Corbin, Yerdanos Asemelash, Steven Sher, Britten K Gordon, Ethan C Whipp, Shaneice Mitchell, Bonnie K Harrington, Shelle...> ;Experimental Hematology & Oncology. 2024 Mar 4
• 2 citations
  A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML.
  Cai, S., Huang, Y., Lance, J., Mao, H., Dunbar, A., McNulty, S., Druley, T., Li, Y., Baer, M., Stock, W., Kovacsovics, T., Blum, W., Schiller, G., Olin, R., Foran, J.,...> ;Blood Advances. 2024 Jan 23
• 1 citations
  Sex-associated differences in frequencies and prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG).
  Michael Ozga, Deedra Nicolet, Krzysztof Mrózek, Ayse S Yilmaz, Jessica Kohlschmidt, Karilyn T Larkin, James S Blachly, Christopher C Oakes, Jill Buss, Christopher J Wa...> ;Leukemia. 2024 Jan 1
• 3 citations
  Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemia.
  Farhad Ravandi, Asad Bashey, James Foran, Wendy Stock, Raya Mawad, Nicholas Short, Musa Yilmaz, Hagop Kantarjian, Olatoyosi Odenike, Anand Patel, Raman Garcha, William...> ;Blood Advances. 2023 Nov 14
• Samples from patients with AML show high concordance in detection of mutations by NGS at local institutions vs central laboratories.
  Uma Borate, Fei Yang, Richard Press, Amy S Ruppert, Dan Jones, Sean Caruthers, Weiqiang Zhao, Jo-Anne Vergilio, Dean C Pavlick, Luke Juckett, Brianna Norris, Taylor Bu...> ;Blood Advances. 2023 Oct 24
• 1 citations
  Phase 1 study of selinexor in combination with salvage chemotherapy in Adults with relapsed or refractory Acute myeloid leukemia.
  Bhavana Bhatnagar, Qiuhong Zhao, Alice S Mims, Sumithira Vasu, Gregory K Behbehani, Karilyn Larkin, James S Blachly, Mohamed A Badawi, Kasey L Hill, Kyle R Dzwigalski,...> ;Leukemia & Lymphoma. 2023 Dec 1
• 3 citations
  Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts.
  Shallis, R., Daver, N., Altman, J., Komrokji, R., Pollyea, D., Badar, T., Bewersdorf, J., Bhatt, V., de Botton, S., de la Fuente Burguera, A., Carraway, H., Desai, P.,...> ;The Lancet. Haematology. 2023 Sep 1
• 2 citations
  Association of social deprivation with survival in younger adult patients with AML: an Alliance study.
  Melanie Rebechi, Jessica Kohlschmidt, Krzysztof Mrózek, Deedra Nicolet, Alice S Mims, James S Blachly, Shelley Orwick, Karilyn T Larkin, Christopher C Oakes, Andrew Ha...> ;Blood Advances. 2023 Aug 8
• 1 citations
  Targeting a xenobiotic transporter to ameliorate vincristine-induced sensory neuropathy.
  Yang Li, Thomas Drabison, Mahesh Nepal, Richard H Ho, Alix F Leblanc, Alice A Gibson, Yan Jin, Wenjian Yang, Kevin M Huang, Muhammad Erfan Uddin, Mingqing Chen, Duncan...> ;JCI Insight. 2023 Jul 24
• 3 citations
  Lenalidomide-associated B-cell ALL: clinical and pathologic correlates and sensitivity to lenalidomide withdrawal.
  Mark B Geyer, Brian C Shaffer, Bhavana Bhatnagar, Alice S Mims, Victoria Klein, Deepika Dilip, Jacob L Glass, Gerard Lozanski, Hani Hassoun, Heather Landau, Yanming Zh...> ;Blood Advances. 2023 Jul 11
• Emerging small molecular inhibitors as targeted therapies for high-risk acute myeloid leukemias.
  Kieran D Sahasrabudhe, Mary Albrethsen, Alice S Mims> ;Expert Review of Hematology. 2023 Jul 23
• Cutaneous graft-versus-host disease within chronic photodamaged skin: A case series demonstrating role for topical 5-fluorouracil.
  Ashley N Gray, Christina Avila, Catherine G Chung, Lucia Seminario-Vidal, Alice Mims, Brittany Dulmage, Karilyn Larkin, Hannah Choe, Samantha Jaglowski, Sumithira Vasu...> ;JAAD Case Reports. 2023 Jun 1
• 4 citations
  Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia.
  Amir T Fathi, Haesook T Kim, Robert J Soiffer, Mark J Levis, Shuli Li, Annette S Kim, Zachariah DeFilipp, Areej El-Jawahri, Steve L McAfee, Andrew M Brunner, Philip C ...> ;Clinical Cancer Research. 2023 Jun 1
• 1 citations
  Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial.
  Vu H Duong, Amy S Ruppert, Alice S Mims, Uma Borate, Eytan M Stein, Maria R Baer, Wendy Stock, Tibor Kovacsovics, William Blum, Martha L Arellano, Gary J Schiller, Reb...> ;Cancer. 2023 Aug 1
• 14 citations
  North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need.
  Naveen Pemmaraju, Hagop Kantarjian, Kendra Sweet, Eunice Wang, Jayastu Senapati, Nathaniel R Wilson, Marina Konopleva, Arthur E Frankel, Vikas Gupta, Ruben Mesa, Matth...> ;Blood. 2023 Feb 9
• 3 citations
  TP-0903 Is Active in Preclinical Models of Acute Myeloid Leukemia withMutation/Deletion.
  Eric D Eisenmann, Jack C Stromatt, Sydney Fobare, Kevin M Huang, Daelynn R Buelow, Shelley Orwick, Jae Yoon Jeon, Robert H Weber, Bill Larsen, Alice S Mims, Erin Hertl...> ;Cancers. 2022 Dec 21
• 3 citations
  Novel investigational approaches for high-risk genetic subsets of AML: TP53, KMT2A, FLT3.
  Kieran D Sahasrabudhe, Alice S Mims> ;Hematology. American Society of Hematology. Education Program. 2022 Dec 9
• 20 citations
  Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for IDH2-mutated myeloid malignancies.
  Fathi, A., Kim, H., Soiffer, R., Levis, M., Li, S., Kim, A., Mims, A., DeFilipp, Z., El-Jawahri, A., McAfee, S., Brunner, A., Narayan, R., Knight, L., Kelley, D., Bott...> ;Blood Advances. 2022 Nov 22
• 1 citations
  Longitudinal Survival Outcomes in Allogeneic Stem Cell Transplantation: An Institutional Experience.
  Justin Jiang, Audrey M Sigmund, Qiuhong Zhao, Patrick Elder, Don M Benson, Sumithira Vasu, Samantha Jaglowski, Alice Mims, Hannah Choe, Karilyn Larkin, Jonathan E Bram...> ;Cancers. 2022 Nov 14
• 5 citations
  Factors Affecting the Cancer Immunotherapeutic Efficacy of T Cell Bispecific Antibodies and Strategies for Improvement.
  Meixiao Long, Alice S Mims, Zihai Li> ;Immunological Investigations. 2022 Nov 1
• 4 citations
  Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance.
  Junhua Lyu, Yuxuan Liu, Lihu Gong, Mingyi Chen, Yazan F Madanat, Yuannyu Zhang, Feng Cai, Zhimin Gu, Hui Cao, Pranita Kaphle, Yoon Jung Kim, Fatma N Kalkan, Helen Step...> ;Cancer Discovery. 2023 Jan 9
• 10 citations
  High early death rates, treatment resistance, and short survival of Black adolescents and young adults with AML.
  Karilyn T Larkin, Deedra Nicolet, Benjamin J Kelly, Krzysztof Mrózek, Stephanie LaHaye, Katherine E Miller, Saranga Wijeratne, Gregory Wheeler, Jessica Kohlschmidt, Ja...> ;Blood Advances. 2022 Oct 11
• Venetoclax and acute myeloid leukaemia: an expanding new frontier.
  Kieran D Sahasrabudhe, Alice S Mims> ;The Lancet. Haematology. 2022 Jun 1
• 13 citations
  Impact of IDH1 and IDH2 mutation detection at diagnosis and in remission in patients with AML receiving allogeneic transplantation.
  Marius Bill, Madlen Jentzsch, Lara Bischof, Jessica Kohlschmidt, Juliane Grimm, Laura Katharina Schmalbrock, Donata Backhaus, Dominic Brauer, Karoline Goldmann, Georg-...> ;Blood Advances. 2023 Feb 14
• Join now to see all

Journal Articles

• Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML  
  Daniel A Pollyea, Amir T Fathi, Geoffrey L Uy, Robert K Stuart, Mikkael A Sekeres, Courtney D DiNardo, Alice S Mims, Eyal C Attar, Richard M Stone, Hagop M Kantarjian,..., The New England Journal of Medicine
• NF1 Mutations Are Recurrent in Adult Acute Myeloid Leukemia and Confer Poor Outcome  
  Eunice S Wang, Bayard L Powell, Richard M Stone, John C Byrd, Clara D Bloomfield, Alice Mims, Andrew J Carroll, Jonathan E Kolitz, James S Blachly, Nature

Abstracts/Posters

• NPM1 mutations Using Deep Amplicon Sequencing and Broad Next Generation Sequencing at the Time of Complete Remission Is Informative to Predicting Risk of Relapse Follo...
  Alice S. Mims, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Effect of Early Post Transplantation Tacrolimus Concentration on the Risk of Acute Graft-Versus-Host Disease in Allogenic Stem Cell Transplantation
  Alice S. Mims, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• The 2017 European Leukemianet Genetic Risk Classification Performs Poorly in Older Patients with Acute Myeloid Leukemia (AML) and Should be Refined to Identify Patient...
  Alice S. Mims, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Precision Medicine Treatment in Older AML: Results of Beat AML Master TrialClinically Relevant Abstract
  Alice S. Mims, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Newly Diagnosed AML Patient Samples Demonstrate High Degree of Concordance in Identification of Pathogenic Mutations By Next Generation Sequencing (NGS) Performed at E...
  Alice S. Mims, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Prevalence of Inherited Cancer Predisposition Mutations in a Cohort of Older AML Patients Enrolled on the Beat AML Master Trial
  Alice S. Mims, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Dose Escalation Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
  Alice S. Mims, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Join now to see all

Lectures

• New Agents in Myeloid Malignancies 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018